1
|
Carney CP, Pandey N, Kapur A, Saadi H, Ong HL, Chen C, Winkles JA, Woodworth GF, Kim AJ. Impact of Targeting Moiety Type and Protein Corona Formation on the Uptake of Fn14-Targeted Nanoparticles by Cancer Cells. ACS NANO 2023; 17:19667-19684. [PMID: 37812740 DOI: 10.1021/acsnano.3c02575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/11/2023]
Abstract
The TWEAK receptor, Fn14, is a promising candidate for active targeting of cancer nanotherapeutics to many solid tumor types, including metastatic breast and primary brain cancers. Targeting of therapeutic nanoparticles (NPs) has been accomplished using a range of targeting moieties including monoclonal antibodies and related fragments, peptides, and small molecules. Here, we investigated a full-length Fn14-specific monoclonal antibody, ITEM4, or an ITEM4-Fab fragment as a targeting moiety to guide the development of a clinical formulation. We formulated NPs with varying densities of the targeting moieties while maintaining the decreased nonspecific adhesivity with receptor targeting (DART) characteristics. To model the conditions that NPs experience following intravenous infusion, we investigated the impact of serum exposure in relation to the targeting moiety type and surface density. To further evaluate performance at the cancer cell level, we performed experiments to assess differences in cellular uptake and trafficking in several cancer cell lines using confocal microscopy, imaging flow cytometry, and total internal reflection fluorescence microscopy. We observed that Fn14-targeted NPs exhibit enhanced cellular uptake in Fn14-high compared to Fn14-low cancer cells and that in both cell lines uptake levels were greater than observed with control, nontargeted NPs. We found that serum exposure increased Fn14-targeted NP specificity while simultaneously reducing the total NP uptake. Importantly, serum exposure caused a larger reduction in cancer cell uptake over time when the targeting moiety was an antibody fragment (Fab region of the monoclonal antibody) compared with the full-length monoclonal antibody targeting moiety. Lastly, we uncovered that full monoclonal antibody-targeted NPs enter cancer cells via clathrin-mediated endocytosis and traffic through the endolysosomal pathway. Taken together, these results support a pathway for developing a clinical formulation using a full-length Fn14 monoclonal antibody as the targeting moiety for a DART cancer nanotherapeutic agent.
Collapse
Affiliation(s)
- Christine P Carney
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
| | - Nikhil Pandey
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
| | - Anshika Kapur
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
| | - Hassan Saadi
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
| | - Hwei Ling Ong
- Secretory Physiology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892, United States
| | - Chixiang Chen
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Department of Epidemiology & Public Health, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
| | - Jeffrey A Winkles
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
| | - Graeme F Woodworth
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Fischell Department of Bioengineering, A. James Clarke School of Engineering, University of Maryland, College Park, Maryland 20742, United States
| | - Anthony J Kim
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Fischell Department of Bioengineering, A. James Clarke School of Engineering, University of Maryland, College Park, Maryland 20742, United States
- Department of Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States
- Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201, United States
| |
Collapse
|
2
|
Zhang Q, Liang J, Bongers A, Richardson JJ, Liang K, Gu Z. Site-Specific Antibody Assembly on Nanoparticles via a Versatile Coating Method for Improved Cell Targeting. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2023; 10:e2206546. [PMID: 36698301 PMCID: PMC10037962 DOI: 10.1002/advs.202206546] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Indexed: 06/17/2023]
Abstract
Antibody-nanoparticle conjugates are promising candidates for precision medicine. However, developing a controllable method for conjugating antibodies to nanoparticles without compromising the antibody activity represents a critical challenge. Here, a facile and generalizable film-coating method is presented using zeolitic imidazole framework-8 (ZIF-8) to immobilize antibodies on various nanoparticles in a favorable orientation for enhanced cell targeting. Different model and therapeutic antibodies (e.g., Herceptin) are assembled on nanoparticles via a biomineralized film-coating method and exhibited high antibody loading and targeting efficiencies. Importantly, the antibodies selectively bind to ZIF-8 via their Fc regions, which favorably exposes the functional Fab regions to the biological target, thus improving the cell targeting ability of antibody-coated nanoparticles. In combination, molecular dynamics simulations and experimental studies on antibody immobilization, orientation efficiency, and biofunctionality collectively demonstrate that this versatile site-specific antibody conjugation method provides effective control over antibody orientation and leads to improved cell targeting for a variety of nanoparticles.
Collapse
Affiliation(s)
- Qianyi Zhang
- School of Chemical EngineeringUniversity of New South WalesSydneyNSW2052Australia
- Australian Centre for NanoMedicine (ACN)University of New South WalesSydneyNSW2052Australia
| | - Jieying Liang
- School of Chemical EngineeringUniversity of New South WalesSydneyNSW2052Australia
- Australian Centre for NanoMedicine (ACN)University of New South WalesSydneyNSW2052Australia
| | - Andre Bongers
- Biological Resources Imaging LaboratoryMark wainwright Analytical CentreThe University of New South WalesSydneyNSW2052Australia
| | | | - Kang Liang
- School of Chemical EngineeringUniversity of New South WalesSydneyNSW2052Australia
- Australian Centre for NanoMedicine (ACN)University of New South WalesSydneyNSW2052Australia
- Graduate School of Biomedical EngineeringThe University of New South WalesSydneyNSW2052Australia
| | - Zi Gu
- School of Chemical EngineeringUniversity of New South WalesSydneyNSW2052Australia
- Australian Centre for NanoMedicine (ACN)University of New South WalesSydneyNSW2052Australia
- UNSW RNA InstituteUniversity of New South WalesSydneyNSW2052Australia
| |
Collapse
|
3
|
Colombo M, Marongiu L, Mingozzi F, Marzi R, Cigni C, Facchini FA, Rotem R, Valache M, Stucchi G, Rocca G, Gornati L, Rizzuto MA, Salvioni L, Zanoni I, Gori A, Prosperi D, Granucci F. Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells. iScience 2022; 25:105042. [PMID: 36124235 PMCID: PMC9482116 DOI: 10.1016/j.isci.2022.105042] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2021] [Revised: 05/04/2022] [Accepted: 08/25/2022] [Indexed: 11/27/2022] Open
Abstract
Calcineurin (CN) inhibitors currently used to avoid transplant rejection block the activation of adaptive immune responses but also prevent the development of tolerance toward the graft, by directly inhibiting T cells. CN, through the transcription factors of the NFAT family, plays an important role also in the differentiation dendritic cells (DCs), the main cells responsible for the activation of T lymphocytes. Therefore, we hypothesized that the inhibition of CN only in DCs and not in T cells could be sufficient to prevent T cell responses, while allowing for the development of tolerance. Here, we show that inhibition of CN/NFAT pathway in innate myeloid cells, using a new nanoconjugate capable of selectively targeting phagocytes in vivo, protects against graft rejection and induces a longer graft acceptance compared to common CN inhibitors. We propose a new generation of nanoparticles-based selective immune suppressive agents for a better control of transplant acceptance. Calcineurin/NFATc2 pathway is required to enable DC migration to draining lymph nodes Calcineurin/NFATc2 pathway in DCs is required for type I immune responses activation Superparamagnetic iron oxide NPs can be used to efficiently target phagocytes in vivo Specific delivery of calcineurin inhibitor by NPs to phagocytes induce graft acceptance
Collapse
Affiliation(s)
- Miriam Colombo
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Laura Marongiu
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Francesca Mingozzi
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Roberta Marzi
- Humabs BioMed, Bellinzona, Canton Ticino, Switzerland
| | - Clara Cigni
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Fabio Alessandro Facchini
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Rany Rotem
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Mihai Valache
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Giulia Stucchi
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Giuseppe Rocca
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Laura Gornati
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Maria Antonietta Rizzuto
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Lucia Salvioni
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
| | - Ivan Zanoni
- Harvard Medical School and Division of Immunology, Division of Gastroenterology, Boston Children’s Hospital, Boston, MA 02115, USA
| | - Alessandro Gori
- Istituto di Scienze e Tecnologie Chimiche, National Research Council of Italy (SCITEC-CNR), Via Mario Bianco, 9, 20131 Milan, Italy
| | - Davide Prosperi
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
- Corresponding author
| | - Francesca Granucci
- Department of Biotechnology and Biosciences, University of Milano - Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
- Corresponding author
| |
Collapse
|
4
|
Saporin Toxin Delivered by Engineered Colloidal Nanoparticles Is Strongly Effective against Cancer Cells. Pharmaceutics 2022; 14:pharmaceutics14071517. [PMID: 35890411 PMCID: PMC9319684 DOI: 10.3390/pharmaceutics14071517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 07/15/2022] [Accepted: 07/18/2022] [Indexed: 02/01/2023] Open
Abstract
Ribosome-inactivating proteins, including Saporin toxin, have found application in the search for innovative alternative cancer therapies to conventional chemo- and radiotherapy. Saporin’s main mechanism of action involves the inhibition of cytoplasmic protein synthesis. Its strong theoretical efficacy is counterbalanced by negligible cell uptake and diffusion into the cytosol. In this work, we demonstrate that by immobilizing Saporin on iron oxide nanoparticles coated with an amphiphilic polymer, which promotes nanoconjugate endosomal escape, a strong cytotoxic effect mediated by ribosomal functional inactivation can be achieved. Cancer cell death was mediated by apoptosis dependent on nanoparticle concentration but independent of surface ligand density. The cytotoxic activity of Saporin-conjugated colloidal nanoparticles proved to be selective against three different cancer cell lines in comparison with healthy fibroblasts.
Collapse
|
5
|
Wu SY, Wu FG, Chen X. Antibody-Incorporated Nanomedicines for Cancer Therapy. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2022; 34:e2109210. [PMID: 35142395 DOI: 10.1002/adma.202109210] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Revised: 02/06/2022] [Indexed: 06/14/2023]
Abstract
Antibody-based cancer therapy, one of the most significant therapeutic strategies, has achieved considerable success and progress over the past decades. Nevertheless, obstacles including limited tumor penetration, short circulation half-lives, undesired immunogenicity, and off-target side effects remain to be overcome for the antibody-based cancer treatment. Owing to the rapid development of nanotechnology, antibody-containing nanomedicines that have been extensively explored to overcome these obstacles have already demonstrated enhanced anticancer efficacy and clinical translation potential. This review intends to offer an overview of the advancements of antibody-incorporated nanoparticulate systems in cancer treatment, together with the nontrivial challenges faced by these next-generation nanomedicines. Diverse strategies of antibody immobilization, formats of antibodies, types of cancer-associated antigens, and anticancer mechanisms of antibody-containing nanomedicines are provided and discussed in this review, with an emphasis on the latest applications. The current limitations and future research directions on antibody-containing nanomedicines are also discussed from different perspectives to provide new insights into the construction of anticancer nanomedicines.
Collapse
Affiliation(s)
- Shun-Yu Wu
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, 2 Sipailou Road, Nanjing, 210096, P. R. China
| | - Fu-Gen Wu
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, 2 Sipailou Road, Nanjing, 210096, P. R. China
| | - Xiaoyuan Chen
- Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore, 119077, Singapore
| |
Collapse
|
6
|
Woythe L, Madhikar P, Feiner-Gracia N, Storm C, Albertazzi L. A Single-Molecule View at Nanoparticle Targeting Selectivity: Correlating Ligand Functionality and Cell Receptor Density. ACS NANO 2022; 16:3785-3796. [PMID: 35274534 PMCID: PMC8945370 DOI: 10.1021/acsnano.1c08277] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Antibody-functionalized nanoparticles (NPs) are commonly used to increase the targeting selectivity toward cells of interest. At a molecular level, the number of functional antibodies on the NP surface and the density of receptors on the target cell determine the targeting interaction. To rationally develop selective NPs, the single-molecule quantitation of both parameters is highly desirable. However, techniques able to count molecules with a nanometric resolution are scarce. Here, we developed a labeling approach to quantify the number of functional cetuximabs conjugated to NPs and the expression of epidermal growth factor receptors (EGFRs) in breast cancer cells using direct stochastic optical reconstruction microscopy (dSTORM). The single-molecule resolution of dSTORM allows quantifying molecules at the nanoscale, giving a detailed insight into the distributions of individual NP ligands and cell receptors. Additionally, we predicted the fraction of accessible antibody-conjugated NPs using a geometrical model, showing that the total number exceeds the accessible number of antibodies. Finally, we correlated the NP functionality, cell receptor density, and NP uptake to identify the highest cell uptake selectivity regimes. We conclude that single-molecule functionality mapping using dSTORM provides a molecular understanding of NP targeting, aiding the rational design of selective nanomedicines.
Collapse
Affiliation(s)
- Laura Woythe
- Department
of Biomedical Engineering, Institute for Complex Molecular Systems
(ICMS), Eindhoven University of Technology, Eindhoven 5612AZ, The Netherlands
| | - Pranav Madhikar
- Department
of Applied Physics, Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Den Dolech 2, 5600MB Eindhoven, The Netherlands
| | - Natalia Feiner-Gracia
- Department
of Biomedical Engineering, Institute for Complex Molecular Systems
(ICMS), Eindhoven University of Technology, Eindhoven 5612AZ, The Netherlands
| | - Cornelis Storm
- Department
of Applied Physics, Institute for Complex Molecular Systems (ICMS), Eindhoven University of Technology, Den Dolech 2, 5600MB Eindhoven, The Netherlands
| | - Lorenzo Albertazzi
- Institute
for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona 08036, Spain
- E-mail:
| |
Collapse
|
7
|
Impact of Tuning the Surface Charge Distribution on Colloidal Iron Oxide Nanoparticle Toxicity Investigated in Caenorhabditis elegans. NANOMATERIALS 2021; 11:nano11061551. [PMID: 34208275 PMCID: PMC8230852 DOI: 10.3390/nano11061551] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 06/09/2021] [Indexed: 01/31/2023]
Abstract
Assessing the toxic effect in living organisms remains a major issue for the development of safe nanomedicines and exposure of researchers involved in the synthesis, handling and manipulation of nanoparticles. In this study, we demonstrate that Caenorhabditis elegans could represent an in vivo model alternative to superior mammalians for the collection of several physiological functionality parameters associated to both short-term and long-term effects of colloidally stable nanoparticles even in absence of microbial feeding, usually reported to be necessary to ensure appropriate intake. Contextually, we investigated the impact of surface charge on toxicity of superparamagnetic iron oxide coated with a wrapping polymeric envelop that confers them optimal colloidal stability. By finely tuning the functional group composition of this shallow polymer–obtaining totally anionic, partially pegylated, partially anionic and partially cationic, respectively–we showed that the ideal surface charge organization to optimize safety of colloidal nanoparticles is the one containing both cationic and anionic groups. Our results are in accordance with previous evidence that zwitterionic nanoparticles allow long circulation, favorable distribution in the tumor area and optimal tumor penetration and thus support the hypothesis that zwitterionic iron oxide nanoparticles could be an excellent solution for diagnostic imaging and therapeutic applications in nanooncology.
Collapse
|
8
|
Garbujo S, Galbiati E, Salvioni L, Mazzucchelli M, Frascotti G, Sun X, Megahed S, Feliu N, Prosperi D, Parak WJ, Colombo M. Functionalization of colloidal nanoparticles with a discrete number of ligands based on a "HALO-bioclick" reaction. Chem Commun (Camb) 2021; 56:11398-11401. [PMID: 32990290 DOI: 10.1039/d0cc04355a] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
A recombinant HALO-GFP fusion protein was designed and isolated to demonstrate the feasibility of controlling the number and orientation of protein ligands to be conjugated on colloidal gold nanoparticles. AuNPs functionalized with exactly one or exactly two GFP molecules exhibited fully preserved functionality of the protein. The method is very straightforward and generally provides highly bioactive nanoparticle-protein conjugates.
Collapse
Affiliation(s)
- Stefania Garbujo
- NanoBioLab, Department of Biotechnology and Bioscience, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Thone MN, Kwon YJ. Extracellular blebs: Artificially-induced extracellular vesicles for facile production and clinical translation. Methods 2019; 177:135-145. [PMID: 31734187 DOI: 10.1016/j.ymeth.2019.11.007] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2019] [Revised: 11/06/2019] [Accepted: 11/10/2019] [Indexed: 12/16/2022] Open
Abstract
Extracellular vesicles (EVs) have emerged as promising biologic and comprehensive therapies for precision medicine. Despite their potential demonstrated at the benchtop, few EV formulations have made it to the clinic due to challenges in regulatory compliant scalable production; including purity, homogeneity, and reproducibility. For translation of this technology, there is a strong need for novel production methods that can meet clinical production criteria. Initial research aimed to address these challenges by taking advantage of natural pathways to increase EV yields. Such "conventional" approaches moderately increased yields but produced inhomogeneous EVs. Additionally, as there are currently no standard methods for isolation, characterization, or quantification, isolated EVs were often impure, contaminated with proteins and other biomacromolecules, and highly diverse in function. The use of shear stress and extrusion methods for EV-like vesicle production has also been investigated. While these processes can produce large EV-like vesicle yields nearly immediately, the harsh processes still result in inhomogeneous loading, and still suffer from poor purity. Chemically-induced membrane blebbing is a promising alternative production method that has the potential to overcome the previously insurmountable barriers of these current methods. This technique produces pure, and well defined EV-like vesicles, termed extracellular blebs (EBs), in clinically relevant scales over the course of minutes to hours. Furthermore, blebbing agents act on the cell in a way which locks the current surface properties and contents, preventing change, allowing for homogeneous EB production, and further preventing post-production changes. EBs may provide a promising pathway for clinical translation of EV technology.
Collapse
Affiliation(s)
- Melissa N Thone
- Department of Chemical and Biomolecular Engineering, University of California, Irvine, CA 92697, United States.
| | - Young Jik Kwon
- Department of Chemical and Biomolecular Engineering, University of California, Irvine, CA 92697, United States; Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, United States; Department of Biomedical Engineering, University of California, Irvine, CA 92697, United States; Department of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, United States.
| |
Collapse
|
10
|
Truffi M, Colombo M, Sorrentino L, Pandolfi L, Mazzucchelli S, Pappalardo F, Pacini C, Allevi R, Bonizzi A, Corsi F, Prosperi D. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells. Sci Rep 2018; 8:6563. [PMID: 29700387 PMCID: PMC5920071 DOI: 10.1038/s41598-018-24968-x] [Citation(s) in RCA: 48] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 04/09/2018] [Indexed: 01/03/2023] Open
Abstract
Targeted therapies have profoundly changed the clinical prospect in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In particular, the anti-HER2 monoclonal antibody trastuzumab represents the gold standard for the treatment of HER2+ breast cancer patients. Its contribution in dampening cancer progression is mainly attributed to the antibody-dependent cell-mediated cytotoxicity (ADCC) rather than HER2 blockade. Here, multiple half chains of trastuzumab were conjugated onto magnetic iron oxide nanoparticles (MNP-HC) to develop target-specific and biologically active nanosystems to enhance anti-HER2 therapeutic potential. HER2 targeting was assessed in different human breast cancer cell lines, where nanoparticles triggered site-specific phosphorylation in the catalytic domain of the receptor and cellular uptake by endocytosis. MNP-HC induced remarkable antiproliferative effect in HER2+ breast cancer cells, exhibiting enhanced activity compared to free drug. Accordingly, nanoparticles induced p27kip1 expression and cell cycle arrest in G1 phase, without loosing capability to prime ADCC. Finally, MNP-HC affected viability of trastuzumab-resistant cells, suggesting interference with the resistance machinery. Our findings indicate that multiple arrangement of trastuzumab half chain on the nanoparticle surface enhances anticancer efficacy in HER2+ breast cancer cells. Powerful inhibition of HER2 signaling could promote responsiveness of resistant cells, thus suggesting ways for drug sensitization.
Collapse
Affiliation(s)
- Marta Truffi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Miriam Colombo
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Luca Sorrentino
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Laura Pandolfi
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Serena Mazzucchelli
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Francesco Pappalardo
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Chiara Pacini
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy
| | - Raffaele Allevi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Arianna Bonizzi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy
| | - Fabio Corsi
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milano, via G. B. Grassi 74, 20157, Milano, Italy. .,Surgery Department, Breast Unit, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100, Pavia, Italy. .,Nanomedicine laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100, Pavia, Italy.
| | - Davide Prosperi
- NanoBioLab, Department of Biotechnologies and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126, Milano, Italy. .,Nanomedicine laboratory, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100, Pavia, Italy.
| |
Collapse
|
11
|
Sivaram AJ, Wardiana A, Howard CB, Mahler SM, Thurecht KJ. Recent Advances in the Generation of Antibody-Nanomaterial Conjugates. Adv Healthc Mater 2018; 7. [PMID: 28961378 DOI: 10.1002/adhm.201700607] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2017] [Revised: 07/31/2017] [Indexed: 01/11/2023]
Abstract
Targeted nanomedicines have significantly changed the way new therapeutics are designed to treat disease. Central to successful therapeutics is the ability to control the dynamics of protein-nanomaterial interactions to enhance the therapeutic effect of the nanomedicine. The aim of this review is to illustrate the diversity and versatility of the conjugation approaches involved in the synthesis of antibody-nanoparticle conjugates, and highlight significant new advances in the field of bioconjugation. Such nanomedicines have found utility as both advanced therapeutic agents, as well as more complex imaging contrast agents that can provide both anatomical and functional information of diseased tissue. While such conjugates show significant promise as next generation targeted nanomedicines, it is recognized that there are in fact no clinically approved targeted therapeutics on the market. This fact is reflected upon within this review, and attempts are made to draw some reasoning from the complexities associated with the bioconjugation chemistry approaches that are typically utilized. Present trends, as well as future directions of next generation targeted nanomedicines are also discussed.
Collapse
Affiliation(s)
- Amal J. Sivaram
- Australian Institute for Bioengineering and Nanotechnology University of Queensland QLD 4072 Australia
- Centre for Advanced Imaging (CAI) University of Queensland QLD 4072 Australia
- ARC Centre of Excellence in Convergent BioNano Science and Technology Queensland Node University of Queensland St Lucia 4072 Australia
| | - Andri Wardiana
- Australian Institute for Bioengineering and Nanotechnology University of Queensland QLD 4072 Australia
| | - Christopher B. Howard
- Australian Institute for Bioengineering and Nanotechnology University of Queensland QLD 4072 Australia
- Centre for Advanced Imaging (CAI) University of Queensland QLD 4072 Australia
- ARC Training Centre for Biopharmaceutical Innovation Brisbane University of Queensland QLD 4072 Australia
| | - Stephen M. Mahler
- Australian Institute for Bioengineering and Nanotechnology University of Queensland QLD 4072 Australia
- ARC Training Centre for Biopharmaceutical Innovation Brisbane University of Queensland QLD 4072 Australia
| | - Kristofer J. Thurecht
- Australian Institute for Bioengineering and Nanotechnology University of Queensland QLD 4072 Australia
- Centre for Advanced Imaging (CAI) University of Queensland QLD 4072 Australia
- ARC Centre of Excellence in Convergent BioNano Science and Technology Queensland Node University of Queensland St Lucia 4072 Australia
| |
Collapse
|
12
|
Pietersz GA, Wang X, Yap ML, Lim B, Peter K. Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies. Nanomedicine (Lond) 2017; 12:1873-1889. [PMID: 28703636 DOI: 10.2217/nnm-2017-0043] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The unique chemical and functional properties of nanoparticles can be harnessed for the delivery of large quantities of various therapeutic biomolecules. Active targeting of nanoparticles by conjugating ligands that bind to target cells strongly facilitates accumulation, internalization into target cells and longer retention at the target site, with consequent enhanced therapeutic effects. Recombinant antibodies with high selectivity and availability for a vast range of targets will dominate the future. In this review, we systematically outline the tremendous progress in the conjugation of antibodies to nanoparticles and the clear advantages that recombinant antibodies offer in the therapeutic targeting of nanoparticles. The demonstrated flexibility of recombinant antibody coupling to nanoparticles highlights the bright future of this technology for modern therapeutic nanomedicine.
Collapse
Affiliation(s)
- Geoffrey A Pietersz
- Baker IDI Heart & Diabetes Institute, Melbourne, Australia.,Department of Immunology, Monash University, Melbourne, Australia.,Burnet Institute, Centre for Biomedical Research, Melbourne, Australia.,Department of Pathology, University of Melbourne, Melbourne, Australia
| | - Xiaowei Wang
- Baker IDI Heart & Diabetes Institute, Melbourne, Australia.,Department of Medicine, Monash University, Melbourne, Australia
| | - May Lin Yap
- Baker IDI Heart & Diabetes Institute, Melbourne, Australia.,Department of Pathology, University of Melbourne, Melbourne, Australia
| | - Bock Lim
- Baker IDI Heart & Diabetes Institute, Melbourne, Australia
| | - Karlheinz Peter
- Baker IDI Heart & Diabetes Institute, Melbourne, Australia.,Department of Immunology, Monash University, Melbourne, Australia.,Department of Medicine, Monash University, Melbourne, Australia
| |
Collapse
|
13
|
Li J, Mao H, Kawazoe N, Chen G. Insight into the interactions between nanoparticles and cells. Biomater Sci 2017; 5:173-189. [DOI: 10.1039/c6bm00714g] [Citation(s) in RCA: 65] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
This review summarizes the latest advances in nanoparticle (NP)–cell interactions. The influence of NP size, shape, shell structure, surface chemistry and protein corona formation on cellular uptake and cytotoxicity is highlighted in detail. Their impact on other cellular responses such as cell proliferation, differentiation and cellular mechanics is also discussed.
Collapse
Affiliation(s)
- Jingchao Li
- International Center for Materials Nanoarchitectonics
- National Institute for Materials Science
- Tsukuba
- Japan
- Department of Materials Science and Engineering
| | - Hongli Mao
- International Center for Materials Nanoarchitectonics
- National Institute for Materials Science
- Tsukuba
- Japan
- Department of Materials Science and Engineering
| | - Naoki Kawazoe
- International Center for Materials Nanoarchitectonics
- National Institute for Materials Science
- Tsukuba
- Japan
| | - Guoping Chen
- International Center for Materials Nanoarchitectonics
- National Institute for Materials Science
- Tsukuba
- Japan
- Department of Materials Science and Engineering
| |
Collapse
|
14
|
Alric C, Aubrey N, Allard-Vannier É, di Tommaso A, Blondy T, Dimier-Poisson I, Chourpa I, Hervé-Aubert K. Covalent conjugation of cysteine-engineered scFv to PEGylated magnetic nanoprobes for immunotargeting of breast cancer cells. RSC Adv 2016. [DOI: 10.1039/c6ra06076e] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Orientation- and site-directed covalent conjugation of cysteine-engineered scFv to PEGylated SPIONs allows antigen recognition while preserving colloidal properties of nanoprobes.
Collapse
Affiliation(s)
- Christophe Alric
- Université François Rabelais de Tours
- EA6295 ‘Nanomédicaments et Nanosondes’
- F 37200 Tours
- France
| | - Nicolas Aubrey
- Université François Rabelais de Tours
- UMR1282 INRA ‘Infectiologie et Santé Publique’
- F 37000 Tours
- France
| | - Émilie Allard-Vannier
- Université François Rabelais de Tours
- EA6295 ‘Nanomédicaments et Nanosondes’
- F 37200 Tours
- France
| | - Anne di Tommaso
- Université François Rabelais de Tours
- UMR1282 INRA ‘Infectiologie et Santé Publique’
- F 37000 Tours
- France
| | - Thibaut Blondy
- Université François Rabelais de Tours
- EA6295 ‘Nanomédicaments et Nanosondes’
- F 37200 Tours
- France
| | - Isabelle Dimier-Poisson
- Université François Rabelais de Tours
- UMR1282 INRA ‘Infectiologie et Santé Publique’
- F 37000 Tours
- France
| | - Igor Chourpa
- Université François Rabelais de Tours
- EA6295 ‘Nanomédicaments et Nanosondes’
- F 37200 Tours
- France
| | - Katel Hervé-Aubert
- Université François Rabelais de Tours
- EA6295 ‘Nanomédicaments et Nanosondes’
- F 37200 Tours
- France
| |
Collapse
|
15
|
Mazzucchelli S, Truffi M, Fiandra L, Sorrentino L, Corsi F. Targeted approaches for HER2 breast cancer therapy: News from nanomedicine? World J Pharmacol 2014; 3:72-85. [DOI: 10.5497/wjp.v3.i4.72] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Revised: 08/29/2014] [Accepted: 09/24/2014] [Indexed: 02/07/2023] Open
Abstract
About 30% of human breast cancers are human epidermal growth factor receptor 2 (HER2)+. This particular biological portrait is characterized by the overexpression of HER2 receptor with the subsequent deregulation of downstream pathways, which control cellular survival and proliferation. The most effective treatment for HER2+ cancer is represented by therapy with HER2-targeted agents. Anti-HER2 therapy dramatically improves clinical outcomes, although it shows some limitations in achieving a proper treatment. These drawbacks of HER2-targeted therapy may be overcome with the development of HER2-targeted drug delivery nanodevices. These nanoparticles possess an internal three-dimensional compartimentalization, which allows to combine the specific target recognition with their capability to act as a drug reservoir for the selective delivery of chemotherapics to tumor sites. Moreover, nanoparticles useful in photothermal ablation or in photodynamic therapy have been functionalized in order to match specificity in tumor cell recognition and suitable chemical properties. Here, we summarize the state of the art concerning the HER2+ breast cancer and anti-HER2 therapy, in particular deepening the contribution of the nanomedicine. Description of preclinical studies performed with HER2-targeted nanoparticles for HER2+ breast cancer therapy will be preceded by an overview on HER2-targeting molecules and nano-conjugation strategies. Further investigation will be necessary to introduce these nano-drugs in clinical practice; however promising results encourage an upcoming translation of this research for the next future.
Collapse
|
16
|
Verderio P, Avvakumova S, Alessio G, Bellini M, Colombo M, Galbiati E, Mazzucchelli S, Avila JP, Santini B, Prosperi D. Delivering colloidal nanoparticles to mammalian cells: a nano-bio interface perspective. Adv Healthc Mater 2014; 3:957-76. [PMID: 24443410 DOI: 10.1002/adhm.201300602] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Revised: 12/05/2013] [Indexed: 01/09/2023]
Abstract
Understanding the behavior of multifunctional colloidal nanoparticles capable of biomolecular targeting remains a fascinating challenge in materials science with dramatic implications in view of a possible clinical translation. In several circumstances, assumptions on structure-activity relationships have failed in determining the expected responses of these complex systems in a biological environment. The present Review depicts the most recent advances about colloidal nanoparticles designed for use as tools for cellular nanobiotechnology, in particular, for the preferential transport through different target compartments, including cell membrane, cytoplasm, mitochondria, and nucleus. Besides the conventional entry mechanisms based on crossing the cellular membrane, an insight into modern physical approaches to quantitatively deliver nanomaterials inside cells, such as microinjection and electro-poration, is provided. Recent hypotheses on how the nanoparticle structure and functionalization may affect the interactions at the nano-bio interface, which in turn mediate the nanoparticle internalization routes, are highlighted. In addition, some hurdles when this small interface faces the physiological environment and how this phenomenon can turn into different unexpected responses, are discussed. Finally, possible future developments oriented to synergistically tailor biological and chemical properties of nanoconjugates to improve the control over nanoparticle transport, which could open new scenarios in the field of nanomedicine, are addressed.
Collapse
Affiliation(s)
- Paolo Verderio
- Dipartimento di Biotecnologie e Bioscienze; Università di Milano-Bicocca; piazza della Scienza 2 20126 Milano Italy
| | - Svetlana Avvakumova
- Dipartimento di Biotecnologie e Bioscienze; Università di Milano-Bicocca; piazza della Scienza 2 20126 Milano Italy
- Dipartimento di Scienze Biomediche e Cliniche “Luigi Sacco”; Università di Milano; Ospedale L. Sacco, via G. B. Grassi 74 20157 Milano Italy
| | - Giulia Alessio
- Dipartimento di Scienze Biomediche e Cliniche “Luigi Sacco”; Università di Milano; Ospedale L. Sacco, via G. B. Grassi 74 20157 Milano Italy
| | - Michela Bellini
- Dipartimento di Biotecnologie e Bioscienze; Università di Milano-Bicocca; piazza della Scienza 2 20126 Milano Italy
| | - Miriam Colombo
- Dipartimento di Biotecnologie e Bioscienze; Università di Milano-Bicocca; piazza della Scienza 2 20126 Milano Italy
| | - Elisabetta Galbiati
- Dipartimento di Biotecnologie e Bioscienze; Università di Milano-Bicocca; piazza della Scienza 2 20126 Milano Italy
| | - Serena Mazzucchelli
- Dipartimento di Scienze Biomediche e Cliniche “Luigi Sacco”; Università di Milano; Ospedale L. Sacco, via G. B. Grassi 74 20157 Milano Italy
| | - Jesus Peñaranda Avila
- Dipartimento di Biotecnologie e Bioscienze; Università di Milano-Bicocca; piazza della Scienza 2 20126 Milano Italy
| | - Benedetta Santini
- Dipartimento di Biotecnologie e Bioscienze; Università di Milano-Bicocca; piazza della Scienza 2 20126 Milano Italy
| | - Davide Prosperi
- Dipartimento di Biotecnologie e Bioscienze; Università di Milano-Bicocca; piazza della Scienza 2 20126 Milano Italy
- Laboratory of Nanomedicine and Clinical Biophotonics, Fondazione Don Carlo Gnocchi ONLUS; Via Capecelatro 66 20148 Milan Italy
| |
Collapse
|
17
|
Biotechnological approaches toward nanoparticle biofunctionalization. Trends Biotechnol 2013; 32:11-20. [PMID: 24182737 DOI: 10.1016/j.tibtech.2013.09.006] [Citation(s) in RCA: 98] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Revised: 09/18/2013] [Accepted: 09/25/2013] [Indexed: 02/06/2023]
Abstract
Nanomedicine has emerged in the past decade as a promising tool for several therapeutic and diagnostic applications. The development of nanoconjugates containing bioactive ligands specific for targeting cancer cell receptors has become a primary objective of modern nanotechnology. The design of ideal nanoconjugates requires optimization of fundamental parameters including size, shape, ligand shell composition, and reduction in nonspecific protein adsorption. Of great importance is the choice of bioconjugation approach, given that it affects the orientation, accessibility, and bioactivity of the targeting molecule. We provide an overview of recent advances in the immobilization of targeting proteins, focusing on methods to control ligand orientation and density, and highlight criteria for nanoparticle design and development required to achieve enhanced receptor-targeting efficiency.
Collapse
|
18
|
Fiandra L, Mazzucchelli S, De Palma C, Colombo M, Allevi R, Sommaruga S, Clementi E, Bellini M, Prosperi D, Corsi F. Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands. ACS NANO 2013; 7:6092-6102. [PMID: 23758591 DOI: 10.1021/nn4018922] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
A great challenge in nanodiagnostics is the identification of new strategies aimed to optimize the detection of primary breast cancer and metastases by the employment of target-specific nanodevices. At present, controversial proof has been provided on the actual importance of surface functionalization of nanoparticles to improve their in vivo localization at the tumor. In the present paper, we have designed and developed a set of multifunctional nanoprobes, modified with three different variants of a model antibody, that is, the humanized monocolonal antibody trastuzumab (TZ), able to selectively target the HER2 receptor in breast cancer cells. Assuming that nanoparticle accumulation in target cells is strictly related to their physicochemical properties, we performed a comparative study of internalization, trafficking, and metabolism in MCF7 cells of multifunctional nanoparticles (MNP) functionalized with TZ or with alternative lower molecular weight variants of the monoclonal antibody, such as the half-chain (HC) and scFv fragments (scFv). Hence, to estimate to what extent the structure of the surface bioligand affects the targeting efficiency of the nanoconjugate, three cognate nanoconstructs were designed, in which only the antibody form was differentiated while the nanoparticle core was maintained unvaried, consisting of an iron oxide spherical nanocrystal coated with an amphiphilic polymer shell. In vitro, in vivo, and ex vivo analyses of the targeting efficiency and of the intracellular fate of MNP-TZ, MNP-HC, and MNP-scFv suggested that the highly stable MNP-HC is the best candidate for application in breast cancer detection. Our results provided evidence that, in this case, active targeting plays an important role in determining the biological activity of the nanoconstruct.
Collapse
Affiliation(s)
- Luisa Fiandra
- Ospedale L. Sacco, via G.B. Grassi 74, 20157 Milano, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|